Published in Transfus Apher Sci on June 06, 2007
Capillary versus venous haemoglobin determination in the assessment of healthy blood donors. Vox Sang (2013) 0.94
Simple paper-based test for measuring blood hemoglobin concentration in resource-limited settings. Clin Chem (2013) 0.94
Evaluation of capillary haemoglobin determination for anaemia screening in blood donation settings. Blood Transfus (2016) 0.79
Blood donation in Nigeria: standard of the donated blood. J Lab Physicians (2012) 0.77
Predicting hemoglobin levels in whole blood donors using transition models and mixed effects models. BMC Med Res Methodol (2013) 0.76
Evaluation of the validity of a rapid method for measuring high and low haemoglobin levels in whole blood donors. Blood Transfus (2012) 0.75
Diagnostic Accuracy of the HemoCue Hb 301, STAT-Site MHgb and URIT-12 Point-of-Care Hemoglobin Meters in a Central Laboratory and a Community Based Clinic in Durban, South Africa. PLoS One (2016) 0.75
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res (2008) 1.97
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet (2010) 1.79
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67
Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica (2009) 1.65
AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica (2008) 1.62
Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med (2011) 1.49
Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol (Engl Ed) (2011) 1.46
[Annexin V levels in survivors of early myocardial infarction]. Rev Esp Cardiol (2002) 1.44
CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. Blood (2011) 1.30
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood (2010) 1.29
Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol (2012) 1.14
[Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction]. Rev Esp Cardiol (2007) 1.13
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
[Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation]. Rev Esp Cardiol (2004) 1.08
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood (2009) 1.04
Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer (2004) 1.03
L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol (2006) 1.03
Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol (2013) 1.02
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost (2013) 1.02
Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke (2004) 1.01
Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models. Am J Pathol (2005) 0.98
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97
Identification of cellular proteins modified in response to African swine fever virus infection by proteomics. Proteomics (2004) 0.95
Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J (2007) 0.95
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke (2006) 0.95
Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J (2008) 0.95
A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood (2006) 0.94
Thrombosis as a conformational disease. Haematologica (2005) 0.93
Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. Haematologica (2011) 0.93
Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica (2005) 0.93
Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood (2007) 0.92
Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol (2007) 0.92
Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res (2008) 0.92
Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Blood (2012) 0.92
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. Lab Invest (2008) 0.92
Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. Haematologica (2009) 0.91
L718P mutation in the membrane-proximal cytoplasmic tail of beta 3 promotes abnormal alpha IIb beta 3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica (2010) 0.91
Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica (2010) 0.90
Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. Am Heart J (2004) 0.90
"Open rather than closed" malonate methano-fullerene derivatives. The formation of methanofulleroid adducts of Y3N@C80. J Am Chem Soc (2007) 0.90
Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int J Cardiol (2010) 0.90
Endothelial protein C receptor polymorphisms and risk of myocardial infarction. Haematologica (2008) 0.89
Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol (2007) 0.89
Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients. Radiat Prot Dosimetry (2007) 0.89
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol (2010) 0.88
Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation (2004) 0.88
Tumor suppressor p27(Kip1) undergoes endolysosomal degradation through its interaction with sorting nexin 6. FASEB J (2010) 0.88
Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation. Breast Cancer Res Treat (2003) 0.88
Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) (2012) 0.87
Treatment of the open abdomen with topical negative pressure therapy: a retrospective study of 46 cases. Int Wound J (2011) 0.87
Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost (2014) 0.86
JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia. Ann Hematol (2008) 0.86
Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res (2012) 0.86
The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica (2007) 0.86
Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab (2009) 0.86